Adco-tenofovir
[(2R)-1-(6-Aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid
Drag to rotate; arrow keys step through the atoms. Structure from PubChem CID 464205.
Registration
- Applicants
- 1
- Registrations
- 1
Applicants and registrations
Variants
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Dolutegravir
Consolidated Schedules 06 July 2026, line 6100
S4: Efavirenz
Consolidated Schedules 06 July 2026, line 6159
S4: Emtricitabine
Consolidated Schedules 06 July 2026, line 6178
S4: Lamivudine
Consolidated Schedules 06 July 2026, line 6850
S4: Tenofovir
Consolidated Schedules 06 July 2026, line 8130
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Background
SAHPRA documents
These documents come from SAHPRA's PI-PIL repository unless the line under a document says otherwise. Always consult with a healthcare professional for medical advice.